<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4766">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594785</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0550</org_study_id>
    <nct_id>NCT04594785</nct_id>
  </id_info>
  <brief_title>Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection</brief_title>
  <acronym>RIPI</acronym>
  <official_title>Evaluation of Post Infectious Inflammatory Reaction (PIIR) in a Retrospective Study Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As Covid 19 manifestations that have been recently described, inflammatory manifestation have&#xD;
      major impact in infectious disease lesions. Some of them are delayed and provide Post&#xD;
      infectious inflammatory reaction (PIIR), they are challenging for diagnosis and for&#xD;
      management. Clinician have to avoid unnecessary antibiotic thearapy and in if necessary have&#xD;
      to give immunosuppressive therapy. Except for rheumatic disease for group A streptococcus&#xD;
      (GAS) infections there are not stanrdized diagnostic criteria and therapeutic protocol, and&#xD;
      PIIR have probably a suboptimal management. In this context the investigators aim to explore&#xD;
      PIIR in the 3 most frequent bacterial invasive infection in France, by a retrospective&#xD;
      monocentric study. The investigators include all children betwwen 2012 and 2018 hospitalized&#xD;
      for infections by Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), and GAS&#xD;
      invasive infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the frequency PIIRs</measure>
    <time_frame>1 day</time_frame>
    <description>Describe the frequency PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection</measure>
    <time_frame>1 day</time_frame>
    <description>Describe the characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Predictors of PIIRs</measure>
    <time_frame>1 day</time_frame>
    <description>Identified the predictors of PIIRs in order to find warning symptoms</description>
  </other_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Streptococcus Pneumonia</condition>
  <condition>Streptococcus Pyogenes Infection</condition>
  <condition>Neisseria Meningitides Meningitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
&#xD;
          -  Fever associated with GAS, NM, or SP invasive infection&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  Impossibility to obtain the consent of parents / legal representatives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric JEZIORSKI</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric JEZIORSKI</last_name>
    <phone>04 67 33 57 98</phone>
    <phone_ext>33</phone_ext>
    <email>e-jeziorski@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jeziorski, MCU-PH</last_name>
      <phone>04 67 33 66 03</phone>
      <phone_ext>33</phone_ext>
      <email>e-jeziorski@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-infectious inflammatory reactions</keyword>
  <keyword>Neisseria Meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

